High response rates can be maintained even after discontinuing combination therapy due to toxic effects, supporting current guidelines for toxicity management.
Supports toxicity management guidelines in combination therapy; extends phase 3 evidence of high post-discontinuation responses to 137 global centers.
occurred at 137 centers throughout the world in the phase 3 trial, which suggests that the skills necessary to safely administer the combination therapy are widely available.Furthermore, and to Valsecchi's point, among the 120 patients who discontinued combination therapy because of toxic effects, the response rate was 67.5%.To us, this supports the current guidelines for management of toxic effects and discontinuation of treatment, since it shows that high response rates can be observed in the context of no treatment-related deaths.Longer followup will be needed to assess the effect of treatment discontinuation on overall survival.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: